Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat

Patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) are at high risk of morbidity and mortality. We previously found that a combination of the farnesoid X receptor agonist cilofexor (CILO) and the acetyl-CoA carboxylase (ACC) inhibitor firsocostat (FIR) improved liver histology and biomarkers in NASH with advanced fibrosis but was associated with hypertriglyceridemia. We evaluated the safety and efficacy of icosapent ethyl (Vascepa ®) and fenofibrate to mitigate triglyceride elevations in NASH patients treated with CILO and FIR.

Source: Clinical Gastroenterology and Hepatology - January 6, 2022 Category: Gastroenterology Authors: Eric J. Lawitz, Bal Raj Bhandari, Peter J. Ruane, Anita Kohli, Eliza Harting, Dora Ding, Jen-Chieh Chuang, Ryan S. Huss, Chuhan Chung, Robert P. Myers, Rohit Loomba Source Type: research